ClinicalTrials.Veeva

Menu

Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients (GA&COVID19)

A

Al-Neelain University

Status and phase

Unknown
Phase 3
Phase 2

Conditions

COVID 19

Treatments

Dietary Supplement: Pectin
Dietary Supplement: Acacia Senegal

Study type

Interventional

Funder types

Other

Identifiers

NCT04381871
GA& COVID19

Details and patient eligibility

About

To study the efficacy of Gum Arabic as an immuno modulator and anti-inflammatory agent among COVID 19 seropositive patients..Half of participants will receive Gum Arabic and the other half will receive placebo

Full description

Randomized placebo controlled trial including COVID 19 seropositive patients will be treated with 30 gram per day for 4 weeks, compared to placebo group treated for the same duration in positive COVID 19 patients.

Blood samples will be taken first at base line level, after two weeks and after the intervention after satisfying the inclusion and exclusion criteria. The main objective is to assess the effect of Gum Arabic (acacia Senegal) on immune system among COVID-19 patients. The outcome of this project understand SARS-CoV-2 immune response in COVID patients and the effect of Gum Arabic (Acacia Senegal) consumption to counteract progression of the disease

Enrollment

110 estimated patients

Sex

All

Ages

5 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • COVID 19 infected as proved by real time PCR (polymerase chain reaction) .( newly diagnosed)

Exclusion criteria

  • Intubated patients on parental treatment

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

110 participants in 2 patient groups, including a placebo group

Intervention Group
Experimental group
Description:
This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose
Treatment:
Dietary Supplement: Acacia Senegal
Control group
Placebo Comparator group
Description:
This group will be provided with pectin powder provided as one-gram-dose
Treatment:
Dietary Supplement: Pectin

Trial contacts and locations

2

Loading...

Central trial contact

Dr Babiker, PhD; Shahenaz Satti, MSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems